Characterization of soy protein hydrolysates and influence of its iron content on monoclonal antibody production by a murine hybridoma cell line
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Biotechnology Progress, 37, (4), John Wiley & Sons
- Ereignis
-
Veröffentlichung
- (wo)
-
Darmstadt
- (wer)
-
Universitäts- und Landesbibliothek
- (wann)
-
2024
- DOI
-
10.26083/tuprints-00021528
- URN
-
urn:nbn:de:tuda-tuprints-215287
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:50 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Djemal, Leila
- Hagen, Jörg von
- Kolmar, Harald
- Deparis, Véronique
- Universitäts- und Landesbibliothek
Entstanden
- 2024
Ähnliche Objekte (12)
Multivalent Functionalized Dextran-Antibody Conjugates for Efficient Tumor Cell Killing
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Novel technologies for antibody hit discovery and engineering of antibody-like proteins with therapeutic relevance
Antibody-mediated inhibition of MHC class I chain-related protein A shedding for tumor therapy
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
X-ray structure of the murine monoclonal antibody MAK33
Monoclonal antibody therapy
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System
TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome
Multivalent Functionalized Dextran-Antibody Conjugates for Efficient Tumor Cell Killing
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Novel technologies for antibody hit discovery and engineering of antibody-like proteins with therapeutic relevance
Antibody-mediated inhibition of MHC class I chain-related protein A shedding for tumor therapy
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
X-ray structure of the murine monoclonal antibody MAK33
Monoclonal antibody therapy
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System
TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome
Multivalent Functionalized Dextran-Antibody Conjugates for Efficient Tumor Cell Killing
Validation and characterization of monoclonal antibodies to target cancer stem cells and to develop new anti-cancer therapies
Improved Drug Delivery of next-generation Antibody-Drug Conjugates by utilizing tumor-associated proteases
Biopolymeric scaffold to achieve high drug-to-antibody ratios using site specific conjugation strategies
Novel technologies for antibody hit discovery and engineering of antibody-like proteins with therapeutic relevance
Antibody-mediated inhibition of MHC class I chain-related protein A shedding for tumor therapy
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
X-ray structure of the murine monoclonal antibody MAK33
Monoclonal antibody therapy
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery
Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System